Compare LARK & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LARK | NOTV |
|---|---|---|
| Founded | 1885 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.8M | 29.9M |
| IPO Year | N/A | 1997 |
| Metric | LARK | NOTV |
|---|---|---|
| Price | $28.50 | $0.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 9.3K | ★ 473.9K |
| Earning Date | 02-03-2026 | 02-04-2026 |
| Dividend Yield | ★ 2.81% | N/A |
| EPS Growth | ★ 38.73 | N/A |
| EPS | ★ 2.84 | N/A |
| Revenue | $64,367,999.00 | ★ $513,024,000.00 |
| Revenue This Year | N/A | $6.26 |
| Revenue Next Year | N/A | $45.49 |
| P/E Ratio | $10.05 | ★ N/A |
| Revenue Growth | ★ 12.95 | 4.54 |
| 52 Week Low | $20.99 | $0.61 |
| 52 Week High | $29.56 | $5.67 |
| Indicator | LARK | NOTV |
|---|---|---|
| Relative Strength Index (RSI) | 57.68 | 30.76 |
| Support Level | $28.00 | $0.61 |
| Resistance Level | $28.98 | $0.86 |
| Average True Range (ATR) | 0.75 | 0.06 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 51.82 | 11.94 |
Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The Bank has continued to focus on increasing its originations of commercial, commercial real estate (CRE), and agricultural loans, which management believes will be more profitable and provide more growth for the Bank than traditional one-to-four-family residential real estate lending. In addition, it also invests in certain investment and mortgage-related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and southwest Kansas.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.